デフォルト表紙
市場調査レポート
商品コード
1799105

製薬とバイオテクノロジーにおける人工知能(AI)の世界市場

Artificial Intelligence (AI) in Pharma and Biotech


出版日
ページ情報
英文 142 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
製薬とバイオテクノロジーにおける人工知能(AI)の世界市場
出版日: 2025年08月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 142 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

製薬とバイオテクノロジーにおける人工知能(AI)の世界市場は2030年までに90億米ドルに達する見込み

2024年に31億米ドルと推定される製薬とバイオテクノロジーにおける人工知能(AI)の世界市場は、2024年から2030年にかけてCAGR 19.2%で成長し、2030年には90億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである創薬・開発アプリケーションは、CAGR 17.9%を記録し、分析期間終了時には26億米ドルに達すると予測されます。臨床試験&最適化アプリケーション分野の成長率は、分析期間中CAGR 17.8%と推定されます。

米国市場は8億2,280万米ドルと推定、中国はCAGR18.3%で成長予測

米国の製薬とバイオテクノロジーにおける人工知能(AI)市場は、2024年に8億2,280万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに14億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは18.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ17.5%と16.8%と予測されています。欧州では、ドイツがCAGR約14.3%で成長すると予測されています。

世界の製薬とバイオテクノロジーにおける人工知能(AI)市場- 主要動向と促進要因まとめ

AIは創薬・開発ライフサイクルにどのような革命をもたらすか?

人工知能は、創薬・開発プロセス全体を加速・最適化することで、製薬・バイオテクノロジー業界を劇的に再構築しています。従来の医薬品開発は高価で時間のかかる取り組みであり、1つの新薬を上市するのに10年以上かかることも多く、数十億米ドルものコストがかかっていました。AIは、ゲノミクス、プロテオミクス、臨床試験記録などの膨大なデータセットの迅速な分析を可能にし、実行可能な創薬ターゲットを特定し、化合物の挙動を予測することで、このパラダイムを変えようとしています。機械学習アルゴリズムは、何千もの潜在的分子をふるいにかけ、予測される有効性、毒性、生物学的利用能に基づいてランク付けすることができ、それによって前臨床スクリーニング段階を合理化することができます。AIによる生成モデルは、指定された治療要件を満たす新規の分子構造を設計することさえできます。さらに、AIはバイオマーカーの選択と検証を改善し、研究者がより効果的に適切な患者集団に薬剤を適合させるのに役立っています。こうした技術革新は、初期段階の研究開発をスピードアップさせるだけでなく、コストのかかる後期臨床試験での失敗リスクも低減させる。自然言語処理ツールは、科学文献、特許、臨床データベースの分析に使用され、これまで見過ごされていた洞察を明らかにしています。実世界のエビデンスと過去のデータを統合することで、AIは予測モデリングを強化し、仮説生成をサポートし、開発中により多くの情報に基づいたゴー/ノーの決定を可能にします。その結果、より俊敏でデータ主導型の創薬モデルが実現し、市場投入までの時間を短縮し、臨床成功の可能性を高めることができます。医薬品開発におけるAIの役割は、もはや実験的なものではありません。AIは医薬品イノベーションに不可欠なツールとなりつつあり、企業が新しい治療法をより迅速かつ効率的に患者に提供できるよう支援しています。

臨床試験、個別化医療、規制遵守においてAIが果たす役割とは?

AIは臨床試験管理、個別化医療、規制当局のワークフローに大きな影響を及ぼしています。この分野は従来、複雑性、変動性、非効率性をはらんでいた。臨床試験では、臨床試験実施における最大のボトルネックの一つである患者募集を最適化するためにAIが導入されています。電子カルテ、遺伝子データ、健康の社会的決定要因を分析することで、AIシステムは適格な患者をより早く特定し、治療へのアドヒアランスや反応の可能性を予測することができます。AIはまた、順応的試験デザインもサポートし、プロトコルは入力データに基づいてリアルタイムで修正され、試験の効率と統計的検出力を向上させる。個別化医療では、AIは個々の患者の生物学的な独自性を解読し、標的療法とマッチングさせる上で極めて重要です。アルゴリズムは、ゲノム配列、タンパク質発現、さらにはマイクロバイオーム・プロファイルを解析し、薬物反応を予測し、副作用を最小限に抑えることで、よりカスタマイズされた治療計画への道を開きます。規制関連業務では、AIがガイドラインの更新、安全性警告、異なる市場にまたがる表示要件の監視を自動化することで、コンプライアンスの確保に役立っています。インテリジェントな文書処理ツールは、提出書類の準備、矛盾の特定、FDAやEMAなどの規制機関とのやりとりの合理化に使用されています。ファーマコビジランスもAIの恩恵を受けている分野で、ソーシャルメディア、臨床記録、市販後報告書などの異種データソースから有害事象シグナルを検出するために機械学習システムが使用されています。このような機能により、手作業を減らし、安全性評価の正確性と適時性を高めることができます。臨床、個別化、規制状況を変革することで、AIは研究室から患者までの道のりを加速するだけでなく、治療がより安全で、より効果的で、より個々のニーズに合ったものになることを保証しています。

製薬会社やバイオテクノロジー企業は、ビジネスモデルや研究開発インフラにどのようにAIを組み込んでいるのか?

製薬企業やバイオテクノロジー企業は、イノベーション主導の状況で競争力を維持するために、AIを中核的な事業戦略や研究開発インフラに組み込む動きを強めています。大手製薬企業は、AIスタートアップやハイテク企業と戦略的パートナーシップを結び、標的同定、化合物スクリーニング、試験最適化のためのプラットフォームを共同開発しています。こうした提携により、専門的な知識や独自のデータセットへのアクセスが可能になり、研究開発のタイムラインを大幅に短縮することができます。また、多くの企業が社内にAIセンター・オブ・エクセレンスを設立し、データサイエンティスト、バイオインフォマティシャン、計算化学者を雇用して、AI能力を部門横断的に統合しています。クラウドベースのプラットフォームと高性能コンピューティングは、ゲノミクス、臨床研究、デジタルヘルスアプリケーションから生成される大量のデータを処理するために採用されています。AI主導のプラットフォームはポートフォリオの優先順位付けに利用され、意思決定者が予測分析に基づいてどの資産を前進させるか、あるいは棚上げするかを評価するのに役立っています。製造面では、AIがプロセスの最適化、品質管理、予知保全をサポートし、一貫した製品品質を確保し、運用コストを削減します。販売・マーケティングでは、AIツールが市場動向、処方パターン、顧客からのフィードバックを分析し、ヘルスケアプロバイダーや患者向けにパーソナライズされたエンゲージメント戦略を策定します。さらに、AIはデジタル治療薬やコンパニオン診断薬の分野でも役割を拡大しており、従来の医薬品とソフトウェア主導のモニタリングや行動介入を組み合わせた統合治療ソリューションの開発を可能にしています。AI中心のビジネスモデルへのシフトは、大企業に限ったことではないです。新興のバイオテクノロジー企業は、差別化を図り、無駄のない経営を構築し、投資を呼び込むために、初日からAIを活用しています。AIが成熟するにつれ、医薬品バリューチェーンの各段階を横断する戦略的イネーブラーになりつつあり、イノベーション、スピード、精度の文化を育んでいます。

製薬・バイオテクノロジー市場におけるAIの持続的な世界的成長の原動力は何か?

医薬品・バイオテクノロジー市場における人工知能の成長は、ヘルスケア需要の高まり、データセットの拡大、技術革新、有利な規制・投資環境の組み合わせによってもたらされます。がん、アルツハイマー病、希少遺伝性疾患など、慢性的で複雑な疾病の世界の負担は、より迅速で効果的な治療ソリューションに対する緊急のニーズを生み出しています。AIは、創薬を加速させ、治療の精度を向上させることで、このニーズに応える一助となります。電子カルテ、ゲノムシークエンシング、ウェアラブルヘルスデバイスの普及により、AIモデルの原動力となる構造化・非構造化データが膨大に蓄積されるようになりました。自然言語処理、機械学習、ニューラルネットワークの技術的進歩により、以前は想像もできなかった方法でこのデータを分析することが可能になり、医薬品開発、臨床意思決定、市場参入戦略の指針となる洞察が解き明かされています。ライフサイエンス分野におけるAIイノベーションの促進を目的とした政府の取り組みや官民パートナーシップも、研究や展開のための資金提供や政策支援を行い、成長を支えています。AIに焦点を当てたバイオベンチャー企業へのベンチャーキャピタル投資は急増を続けており、これはAIを活用した医薬品開発の市場開拓の可能性に対する強い自信を反映しています。精密医療の出現と患者中心のヘルスケアの推進は、個別化治療戦略を可能にするAIツールへの需要をさらに強めています。世界の製薬企業もコスト削減と研究開発効率の向上を迫られており、AIはイノベーションを持続するための有力なソリューションとなっています。AIが発見した新薬候補が臨床試験に入るなど、成功事例が増えるにつれ、ライフサイエンス分野におけるAIの信頼性と採用は拡大し続けています。これらの要因が相まって、製薬・バイオテクノロジー分野におけるAI市場の堅調かつ持続的な拡大が促進され、データ主導でテクノロジーを駆使したヘルスケア・イノベーションの新時代が到来する兆しを見せています。

セグメント

アプリケーション(創薬・開発アプリケーション、臨床試験・最適化アプリケーション、予測保守・品質管理アプリケーション、創薬標的同定アプリケーション、疾病診断・予後アプリケーション、その他アプリケーション)、エンドユーザー(製薬・バイオテクノロジー企業エンドユーザー、学術・研究機関エンドユーザー、その他エンドユーザー)

調査対象企業の例

  • AbbVie
  • AstraZeneca
  • Biogen
  • Boehringer Ingelheim
  • CureMetrix
  • Exscientia
  • Flatiron Health
  • GSK
  • IBM Watson Health
  • Insilico Medicine
  • Johnson & Johnson
  • Lilly
  • Medtronic
  • Merck & Co.
  • NVIDIA
  • PathAI
  • Recursion Pharmaceuticals
  • Sanofi
  • Tempus
  • Zymergen

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入(完成品とOEM)に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価(COGS)の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP38499

Global Artificial Intelligence (AI) in Pharma and Biotech Market to Reach US$9.0 Billion by 2030

The global market for Artificial Intelligence (AI) in Pharma and Biotech estimated at US$3.1 Billion in the year 2024, is expected to reach US$9.0 Billion by 2030, growing at a CAGR of 19.2% over the analysis period 2024-2030. Drug Discovery & Development Application, one of the segments analyzed in the report, is expected to record a 17.9% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Clinical Trials & Optimization Application segment is estimated at 17.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$822.8 Million While China is Forecast to Grow at 18.3% CAGR

The Artificial Intelligence (AI) in Pharma and Biotech market in the U.S. is estimated at US$822.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 18.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.5% and 16.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.3% CAGR.

Global Artificial Intelligence (AI) in Pharma and Biotech Market - Key Trends & Drivers Summarized

How Is AI Revolutionizing the Drug Discovery and Development Lifecycle?

Artificial Intelligence is dramatically reshaping the pharmaceutical and biotechnology industries by accelerating and optimizing the entire drug discovery and development process. Traditional drug development is an expensive, time-consuming endeavor that often takes over a decade and costs billions of dollars to bring a single new drug to market. AI is changing this paradigm by enabling the rapid analysis of massive datasets, such as genomics, proteomics, and clinical trial records, to identify viable drug targets and predict the behavior of chemical compounds. Machine learning algorithms can sift through thousands of potential molecules and rank them based on predicted efficacy, toxicity, and bioavailability, thereby streamlining the preclinical screening phase. Generative AI models are even capable of designing novel molecular structures that meet specified therapeutic requirements. Moreover, AI is improving the selection and validation of biomarkers, helping researchers match drugs to the right patient populations more effectively. These innovations not only speed up early-stage R&D but also reduce the risk of failure in costly late-stage trials. Natural language processing tools are being used to analyze scientific literature, patents, and clinical databases to uncover previously overlooked insights. By integrating real-world evidence and historical data, AI enhances predictive modeling, supports hypothesis generation, and allows for more informed go/no-go decisions during development. The net result is a more agile and data-driven drug discovery model, reducing time to market and improving the chances of clinical success. AI’s role in drug development is no longer experimental; it is becoming an essential tool for pharmaceutical innovation, helping companies bring new treatments to patients faster and more efficiently.

What Role Is AI Playing in Clinical Trials, Personalized Medicine, and Regulatory Compliance?

AI is making a profound impact on clinical trial management, personalized medicine, and regulatory workflows, areas that are traditionally laden with complexity, variability, and inefficiency. In clinical trials, AI is being deployed to optimize patient recruitment, one of the biggest bottlenecks in trial execution. By analyzing electronic health records, genetic data, and social determinants of health, AI systems can identify eligible patients faster and predict their likelihood of adherence and response to treatment. AI also supports adaptive trial designs, where protocols are modified in real-time based on incoming data, improving trial efficiency and statistical power. For personalized medicine, AI is crucial in deciphering the biological uniqueness of individual patients and matching them with targeted therapies. Algorithms analyze genomic sequences, protein expressions, and even microbiome profiles to predict drug response and minimize adverse effects, paving the way for more customized treatment plans. In regulatory affairs, AI helps ensure compliance by automating the monitoring of guideline updates, safety alerts, and labeling requirements across different markets. Intelligent document processing tools are being used to prepare submissions, identify inconsistencies, and streamline interactions with regulatory agencies such as the FDA and EMA. Pharmacovigilance is another area benefiting from AI, where machine learning systems are used to detect adverse event signals from disparate data sources, including social media, clinical notes, and post-marketing reports. These capabilities reduce manual workload and enhance the accuracy and timeliness of safety assessments. By transforming the clinical, personalized, and regulatory landscape, AI is not only accelerating the path from lab to patient but also ensuring that treatments are safer, more effective, and more tailored to individual needs.

How Are Pharma and Biotech Companies Integrating AI into Their Business Models and R&D Infrastructure?

Pharma and biotech companies are increasingly embedding AI into their core business strategies and R&D infrastructure to stay competitive in an innovation-driven landscape. Large pharmaceutical firms are forming strategic partnerships with AI startups and tech companies to co-develop platforms for target identification, compound screening, and trial optimization. These collaborations enable access to specialized expertise and proprietary datasets that can significantly accelerate R&D timelines. Many companies are also establishing internal AI centers of excellence, hiring data scientists, bioinformaticians, and computational chemists to integrate AI capabilities across departments. Cloud-based platforms and high-performance computing are being adopted to handle the massive volume of data generated from genomics, clinical studies, and digital health applications. AI-driven platforms are being used for portfolio prioritization, helping decision-makers assess which assets to advance or shelve based on predictive analytics. On the manufacturing side, AI supports process optimization, quality control, and predictive maintenance, ensuring consistent product quality and reducing operational costs. In sales and marketing, AI tools analyze market trends, prescription patterns, and customer feedback to develop personalized engagement strategies for healthcare providers and patients. Additionally, AI is playing a growing role in digital therapeutics and companion diagnostics, enabling the development of integrated treatment solutions that combine traditional drugs with software-driven monitoring and behavioral interventions. This shift toward AI-centric business models is not limited to large enterprises. Emerging biotech firms are using AI from day one to differentiate themselves, build leaner operations, and attract investment. As AI matures, it is becoming a strategic enabler that cuts across every phase of the pharmaceutical value chain, fostering a culture of innovation, speed, and precision.

What Is Driving the Sustained Global Growth of AI in the Pharma and Biotech Market?

The growth in the artificial intelligence in pharma and biotech market is driven by a combination of rising healthcare demands, expanding datasets, technological innovation, and a favorable regulatory and investment environment. The global burden of chronic and complex diseases such as cancer, Alzheimer’s, and rare genetic disorders is creating an urgent need for faster and more effective therapeutic solutions. AI helps meet this need by accelerating drug discovery and improving treatment precision. The widespread adoption of electronic health records, genomic sequencing, and wearable health devices has created a vast and growing pool of structured and unstructured data that fuels AI models. Technological advancements in natural language processing, machine learning, and neural networks have made it possible to analyze this data in ways that were previously unimaginable, unlocking insights that guide drug development, clinical decision-making, and market access strategies. Government initiatives and public-private partnerships aimed at fostering AI innovation in life sciences are also supporting growth, providing funding and policy support for research and deployment. Venture capital investment in AI-focused biotech startups continues to surge, reflecting strong confidence in the market potential of AI-driven drug development. The emergence of precision medicine and the push for patient-centric healthcare are further reinforcing the demand for AI tools that enable personalized treatment strategies. Global pharmaceutical companies are also under pressure to reduce costs and improve R&D efficiency, making AI a compelling solution for sustaining innovation. As more success stories emerge, such as AI-discovered drug candidates entering clinical trials, the credibility and adoption of AI in the life sciences continue to grow. These factors are collectively fueling a robust and sustained expansion of the AI market within the pharma and biotech sectors, signaling a new era of data-driven, technology-enabled healthcare innovation.

SCOPE OF STUDY:

The report analyzes the Artificial Intelligence (AI) in Pharma and Biotech market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application, Other Applications); End-User (Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

  • AbbVie
  • AstraZeneca
  • Biogen
  • Boehringer Ingelheim
  • CureMetrix
  • Exscientia
  • Flatiron Health
  • GSK
  • IBM Watson Health
  • Insilico Medicine
  • Johnson & Johnson
  • Lilly
  • Medtronic
  • Merck & Co.
  • NVIDIA
  • PathAI
  • Recursion Pharmaceuticals
  • Sanofi
  • Tempus
  • Zymergen

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Artificial Intelligence (AI) in Pharma and Biotech - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising R&D Costs and Long Development Cycles Spur Demand for AI-Driven Drug Discovery and Optimization Platforms
    • Here's How Generative AI Strengthens the Business Case for De Novo Molecule Design and Target Prediction
    • Integration of AI with Omics and Real-World Data Throws the Spotlight on Precision Medicine and Biomarker Discovery
    • Here's the Story: Natural Language Processing Enables Deep Mining of Scientific Literature and Biomedical Databases
    • AI-Powered Predictive Modeling Enhances Compound Screening, Toxicity Assessment, and Lead Candidate Prioritization
    • Digital Twins and Simulation Technologies Expand the Addressable Market for In Silico Testing and Virtual Clinical Trials
    • AI in Bioprocess Optimization and Manufacturing Improves Yield, Scalability, and Quality Control in Biotech Operations
    • Growing Focus on Rare Diseases and Orphan Drug Development Supports Use of AI to Identify Small, High-Impact Patient Populations
    • Here's the Story: Regulatory Acceptance of AI in Drug Development Workflows Drives Frameworks for Validation and Compliance
    • Integration of AI in Pharmacovigilance Enhances Post-Marketing Surveillance and Signal Detection Capabilities
    • Expansion of AI-Powered Platforms in Vaccine Development Demonstrates Potential in Rapid Response to Emerging Pathogens
    • Here's How Cloud Infrastructure and Data Interoperability Accelerate the Scalability of AI Tools Across the Drug Development Lifecycle
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Artificial Intelligence (AI) in Pharma and Biotech Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Drug Discovery & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Drug Discovery & Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Clinical Trials & Optimization Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Clinical Trials & Optimization Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Predictive Maintenance & Quality Control Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Predictive Maintenance & Quality Control Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Drug Target Identification Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Drug Target Identification Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Disease Diagnosis & Prognosis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Disease Diagnosis & Prognosis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Pharma & Biotech Companies End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Academic & Contract Research Organizations End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Academic & Contract Research Organizations End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 22: USA Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • JAPAN
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 30: Japan Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Japan 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • CHINA
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 34: China Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: China 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 36: China Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: China 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • EUROPE
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: Europe 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 40: Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Europe 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 42: Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Europe 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • FRANCE
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 44: France Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: France 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 46: France Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: France 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • GERMANY
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 48: Germany Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Germany 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 50: Germany Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Germany 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • ITALY
    • TABLE 52: Italy Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Italy 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 54: Italy Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Italy 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • UNITED KINGDOM
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 56: UK Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: UK 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 58: UK Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: UK 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 60: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of Europe 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of Europe 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Artificial Intelligence (AI) in Pharma and Biotech Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 64: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Asia-Pacific 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 66: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Asia-Pacific 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 68: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by Application - Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Rest of World 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development Application, Clinical Trials & Optimization Application, Predictive Maintenance & Quality Control Application, Drug Target Identification Application, Disease Diagnosis & Prognosis Application and Other Applications for the Years 2025 & 2030
    • TABLE 70: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Rest of World 6-Year Perspective for Artificial Intelligence (AI) in Pharma and Biotech by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-User, Academic & Contract Research Organizations End-User and Other End-Users for the Years 2025 & 2030

IV. COMPETITION